UniProt Q8IYT8 · PDB · AlphaFold · Substrate: MBP · Clone: aa 1-631medium-confidence target
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Brigatinib | 81.5% | 18.5% | 82.96 | 0.513 |
| 2 | Palbociclib | 80.1% | 19.9% | 98.75 | 0.673 |
| 3 | Sunitinib | 62.1% | 37.9% | 91.73 | 0.524 |
| 4 | Fedratinib | 52.9% | 47.1% | 96.21 | 0.576 |
| 5 | Axitinib | 52.7% | 47.3% | 93.23 | 0.688 |
| 6 | Defactinib | 45.7% | 54.3% | 92.68 | 0.450 |
| 7 | Dabrafenib | 42.6% | 57.4% | 94.74 | 0.633 |
| 8 | Ceritinib | 39.3% | 60.7% | 95.44 | 0.618 |
| 9 | Ponatinib | 35.5% | 64.5% | 78.23 | 0.534 |
| 10 | Crizotinib | 29.6% | 70.4% | 91.39 | 0.581 |
| 11 | Bosutinib | 27.5% | 72.5% | 87.22 | 0.555 |
| 12 | Baricitinib | 23.1% | 76.9% | 97.99 | 0.616 |
| 13 | Abemaciclib | 15.5% | 84.5% | 91.48 | 0.563 |
| 14 | Pirtobrutinib | 13.0% | 87.0% | 99.49 | 0.656 |
| 15 | Neratinib | 12.7% | 87.3% | 93.18 | 0.597 |
| 16 | Selpercatinib | 12.5% | 87.5% | 96.72 | 0.635 |
| 17 | Ruxolitinib | 11.8% | 88.2% | 98.25 | 0.592 |
| 18 | Fostamatinib | 11.1% | 88.9% | 96.74 | 0.613 |
| 19 | Tenalisib | 8.5% | 91.5% | 97.98 | 0.702 |
| 20 | Repotrectinib | 8.2% | 91.8% | 84.21 | 0.608 |
Paralog block
ULK1, ULK2, ULK3
EMT expression
- Mesenchymal log2(TPM+1): 2.56
- Epithelial log2(TPM+1): 1.92
- Fold change: 0.64
- Status: No significant change
High-confidence drugs
- Palbociclib — inh 80.1% · KISS 30.77
- Brigatinib — inh 81.5% · KISS 12.36
- Sunitinib — inh 62.1% · KISS -5.52
Selectivity landscape vs inhibition on ULK2
Each point is one of the 92 approved drugs; color = inhibition % on ULK2.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…